Table 1.

Patients’ Characteristics

No. Morphology Cytogenetics % Blasts CD34*% RhoDClinical Response†
 1. AML-M1  Normal  59  neg <10  CCR  
 2. AML-M2  Normal  78  neg  <10 Rel within 6 mo  
 3. AML-M4  inv (3), −7  71  pos 33  PRes  
 4. AML-AUL  num ab  63  neg  27 PRes  
 5. AML-M4  Normal  57  neg  <10  PRes 
 6. AML-M2  t(7;11)  29  pos  <10  CCR 
 7. AML-M3  t(15;17)  64  neg  17  CCR 
 8. AML-M4  t(8;21)  62  pos  14  Rel after 2 yr 
 9. AML-M5b  Normal  64  neg  18  Rel within 1 yr 
10. AML-M2  t(8;21)  87  pos  11  Rel after 2 yr 
11. AML-M4  num ab  76  ND  24  PRes 
No. Morphology Cytogenetics % Blasts CD34*% RhoDClinical Response†
 1. AML-M1  Normal  59  neg <10  CCR  
 2. AML-M2  Normal  78  neg  <10 Rel within 6 mo  
 3. AML-M4  inv (3), −7  71  pos 33  PRes  
 4. AML-AUL  num ab  63  neg  27 PRes  
 5. AML-M4  Normal  57  neg  <10  PRes 
 6. AML-M2  t(7;11)  29  pos  <10  CCR 
 7. AML-M3  t(15;17)  64  neg  17  CCR 
 8. AML-M4  t(8;21)  62  pos  14  Rel after 2 yr 
 9. AML-M5b  Normal  64  neg  18  Rel within 1 yr 
10. AML-M2  t(8;21)  87  pos  11  Rel after 2 yr 
11. AML-M4  num ab  76  ND  24  PRes 

Abbreviations: CCR, continued complete remission; PRes, primary resistant; Rel, relapse; num ab, numerous aberrations; pos, positive; neg, negative; ND, not done.

*

Positive: >30% CD34 expressing cells.

†

Clinical response after anthracycline-containing regimen.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal